Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01514266 · ClinicalTrials.gov registry record · NA

Effect of Curcumin on Lung Inflammation

A NA study, sponsored by Baylor College of Medicine.

Completed
Registry status
NA
Development phase
57
Enrollment target

NCT01514266 is a NA study that has completed, run by Baylor College of Medicine. The registered enrollment target is 57 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01514266, a NA study, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
NA
Development phase
57 participants
Enrollment target

Study Summary

Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes of death and health care use. Diffuse airways inflammation is seen in COPD and is thought to be the reason for deterioration of lung function in COPD. Currently there is no medication available that can modify or reduce this inflammation. Furthermore, from literature review it has been shown that chronic inflammation can result in cancerous changes. Curcumin is a food additive used for centuries. Several studies showed that curcumin suppress the different inflammatory pathways. Specially, the TNF-alpha and the NF kappa-b are down regulated by this substance. This study was designed to evaluate effect of combination of curcumin+Bioprine on sputum cytology in patients with COPD. This is double-blind randomized pilot study.

Interventions

  • DRUG Placebo
  • DRUG Curcumin+Bioprine

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2005-04
Est. Completion 2010-08
Phase NA

Sponsor

Baylor College of Medicine

616 total trials

What the Registry Record Tells You About NCT01514266

The ClinicalTrials.gov registry entry for NCT01514266 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01514266 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01514266 about?

NCT01514266 is a clinical study titled "Effect of Curcumin on Lung Inflammation". Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes of death and health care use. Diffuse airways inflammation is seen in COPD and is thought to be the reason for deterioration of lung function in COPD. Currently there is no medication available that can modify or reduce ...

What is the current status of trial NCT01514266?

This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2005-04. Estimated completion is 2010-08.

What interventions are being tested in trial NCT01514266?

The interventions under investigation include: Placebo (DRUG), Curcumin+Bioprine (DRUG).

Who is sponsoring clinical trial NCT01514266?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.